The importance of Minerva Surgical v Hologic

On January 8, 2021, the US Supreme Court agreed to hear Minerva Surgical v Hologic to consider whether an inventor or those in privity with the inventor may assert patent invalidity as a defence against a patent infringement suit for the inventor’s patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

Fed Circuit rejects Minerva patent invalidation bid

12 August 2022 Hologic patent invented by Minerva’s founder cannot be invalidated | Patent in dispute concerns device used to treat uterine bleeding | US Court of Appeals.

Big Pharma

Minerva: less risk for inventors, more work for the courts

1 July 2021 The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.

Americas

Breaking: SCOTUS says inventors can challenge their patents, but imposes limits

29 June 2021 The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope.